|Bid||4.6100 x 900|
|Ask||4.6700 x 1100|
|Day's range||4.6300 - 4.8000|
|52-week range||4.0600 - 11.1000|
|Beta (5Y monthly)||1.70|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.70|
BOULDER, Colo., September 20, 2021--Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shares of the biotech that focuses on oncology drugs climbed more than 12% during the week.